R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

How birth tissue donations are fuelling the cell therapy rev...

As the burgeoning field of cell therapy evolves, so do the practices around obtaining the raw biological material needed to create these life-changing treatments.

R&D

The power of data science platforms to cut through the compl...

Biopharmaceutical companies across the globe are rapidly expanding their pipelines as they aim to break new ground in different disease areas, on behalf of patients awaiting life-changing t

R&D

Talking techbio with NVIDIA: Accelerated computing, NLP, and...

As Genentech and NVIDIA enter into a multi-year strategic AI research collaboration to accelerate drug discovery and development, web editor Nicole Raleigh revisits a recent discussion with

R&D

A forgotten opioid epidemic, but a mounting problem

Deaths from opioid-related overdoses continue to grow in the US, but public health events of recent times mean that attention has been focused elsewhere.

R&D

Immunometabolism: Providing a new era of targeted medicine

In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh speaks with Neil Weir, CEO of Sitryx Therapeutics, a smaller biotech that specialises in immunometabolism – a rapidly

R&D

Modernising clinical trials: The PARTICIPATE framework

Each year, a staggering 67 million individuals lose their lives.1 Heart disease account for approximately 17.9 million of these deaths,2 and cancer takes away 10 milli